PLXNA3: A Potential Drug Target Or Biomarker for Cancer, Neurodegenerative Diseases and Developmental Disorders

Target Name: PLXNA3

NCBI ID: G55558

PLXNA3

PLXNA3: A Potential Drug Target Or Biomarker for Cancer, Neurodegenerative Diseases and Developmental Disorders

PLXNA3 (6.3) is a protein that is expressed in the human placenta, and it is involved in the development and maintenance of the placenta. The placenta plays a critical role in the pregnancy, as it provides nutrients and oxygen to the developing fetus, and removes waste products from the body. PLXNA3 is one of the proteins that is expressed in the placenta, and it has been shown to be involved in several important functions in the placenta, including cell adhesion, migration, and angiogenesis.

Recent studies have suggested that PLXNA3 may be a drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. This is because PLXNA3 is involved in several important processes that are disrupted in these diseases, and may provide a unique target for therapeutic intervention.

One of the potential mechanisms by which PLXNA3 may be involved in cancer is its role in cell adhesion and migration. Many cancer cells are able to migrate and invade surrounding tissues, and this process is a key step in the development of cancer. PLXNA3 has been shown to be involved in the regulation of cell adhesion and migration, and may play a role in the development and progression of cancer. Therefore, PLXNA3 may be an attractive target for cancer therapies that aim to inhibit these processes.

Another potential mechanism by which PLXNA3 may be involved in neurodegenerative diseases is its role in the regulation of axon growth and differentiation. Many neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of nerve cells and the damage to axons that support these cells. PLXNA3 has been shown to be involved in the regulation of axon growth and differentiation, and may play a role in the development and progression of these diseases. Therefore, PLXNA3 may be an attractive target for therapies that aim to slow down or reverse the progression of these conditions.

PLXNA3 may also be involved in the development and progression of developmental disorders, such as Down syndrome. Down syndrome is a genetic disorder that is characterized by a range of developmental and cognitive impairments, and is caused by a deficiency of the dystrophin gene. PLXNA3 has been shown to be involved in the regulation of dystrophin function, and may play a role in the development and progression of Down syndrome. Therefore, PLXNA3 may be an attractive target for therapies that aim to treat these conditions.

In conclusion, PLXNA3 is a protein that is expressed in the human placenta and is involved in several important functions in this organ. Recent studies have suggested that PLXNA3 may be an attractive drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. Further research is needed to fully understand the role of PLXNA3 in these processes and to develop effective therapies that target this protein.

Protein Name: Plexin A3

Functions: Coreceptor for SEMA3A and SEMA3F. Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance in the developing nervous system. Regulates the migration of sympathetic neurons, but not of neural crest precursors. Required for normal dendrite spine morphology in pyramidal neurons. May play a role in regulating semaphorin-mediated programmed cell death in the developing nervous system. Class 3 semaphorins bind to a complex composed of a neuropilin and a plexin. The plexin modulates the affinity of the complex for specific semaphorins, and its cytoplasmic domain is required for the activation of down-stream signaling events in the cytoplasm

The "PLXNA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLXNA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets